Unveiling the multifaceted role of adropin in various diseases (Review)
- Authors:
- Ling Chen
- Jianrao Lu
- Jing Hu
- Xuezhong Gong
-
Affiliations: Department of Nephrology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China, Department of Nephrology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China, Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, P.R. China - Published online on: August 13, 2024 https://doi.org/10.3892/ijmm.2024.5414
- Article Number: 90
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, et al: Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 8:468–481. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Marczuk N, Cecerska-Heryć E, Jesionowska A and Dołęgowska B: Adropin-physiological and pathophysiological role. Postepy Hig Med Dosw (Online). 70:981–988. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, Sahin I, Kocaman N, Citil C and Kendir Y: Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 380:73–81. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Chen S, Shen T, Yang W, Chen Q, Zhang P, You Y, Sun X, Xu H, Tang Y, et al: Adropin regulates hepatic glucose production via PP2A/AMPK pathway in insulin-resistant hepatocytes. FASEB J. 34:10056–10072. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Erman H, Ozdemir A, Sitar ME, Cetin SI and Boyuk B: Role of serum adropin measurement in the assessment of insulin resistance in obesity. J Investig Med. 69:1318–1323. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Akcılar R, Emel Koçak F, Şimşek H, Akcılar A, Bayat Z, Ece E and Kökdaşgil H: The effect of adropin on lipid and glucose metabolism in rats with hyperlipidemia. Iran J Basic Med Sci. 19:245–251. 2016. | |
|
Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW and Butler AA: Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 4:310–324. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yu M, Wang D, Zhong D, Xie W and Luo J: adropin carried by reactive oxygen species-responsive nanocapsules ameliorates renal lipid toxicity in diabetic mice. ACS Appl Mater Interfaces. 14:37330–37344. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, Al-Omran M, Teoh H and Verma S: Adropin is a novel regulator of endothelial function. Circulation. 122(11 Suppl): S185–S192. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Jin F, Wang P, Hou S, Jin T, Chang X and Zhao L: Adropin inhibits vascular smooth muscle cell osteogenic differentiation to alleviate vascular calcification via the JAK2/STAT3 signaling pathway. Biomed Res Int. 2022:91222642022.PubMed/NCBI | |
|
Ali II, D'Souza C, Singh J and Adeghate E: Adropin's role in energy homeostasis and metabolic disorders. Int J Mol Sci. 23:83182022. View Article : Google Scholar : PubMed/NCBI | |
|
Jasaszwili M, Billert M, Strowski MZ, Nowak KW and Skrzypski M: Adropin as A Fat-Burning hormone with multiple functions-review of a decade of research. Molecules. 25:5492020. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Xie W, Zheng XL, Yin WD and Tang CK: A novel peptide adropin in cardiovascular diseases. Clin Chim Acta. 453:107–113. 2016. View Article : Google Scholar | |
|
Niepolski L and Grzegorzewska AE: Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis. Adv Med Sci. 61:282–287. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Petersen TN, Brunak S, von Heijne G and Nielsen H: SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 8:785–786. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wong CM, Wang Y, Lee JT, Huang Z, Wu D, Xu A and Lam KS: Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem. 289:25976–25986. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Yan Y, Zhang Q and Jiang Q: Molecular cloning and characterization of the novel adropin from tilapia (Oreochromis niloticus): Involvement in the control of food intake. Neuropeptides. 88:1021652021. View Article : Google Scholar : PubMed/NCBI | |
|
Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, Culler MD, Mynatt RL and Butler AA: Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 20:1394–1402. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bindesbøll C, Fan Q, Nørgaard RC, MacPherson L, Ruan HB, Wu J, Pedersen TA, Steffensen KR, Yang X, Matthews J, et al: Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity. J Lipid Res. 56:771–785. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Stayrook KR, Rogers PM, Savkur RS, Wang Y, Su C, Varga G, Bu X, Wei T, Nagpal S, Liu XS and Burris TP: Regulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha. Mol Pharmacol. 73:607–612. 2008. View Article : Google Scholar | |
|
Ghoshal S, Stevens JR, Billon C, Girardet C, Sitaula S, Leon AS, Rao DC, Skinner JS, Rankinen T, Bouchard C, et al: Adropin: An endocrine link between the biological clock and cholesterol homeostasis. Mol Metab. 8:51–64. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Meda C, Dolce A, Vegeto E, Maggi A and Della Torre S: ERα-Dependent regulation of adropin predicts sex differences in liver homeostasis during high-fat diet. Nutrients. 14:32622022. View Article : Google Scholar | |
|
Stokar J, Gurt I, Cohen-Kfir E, Yakubovsky O, Hallak N, Benyamini H, Lishinsky N, Offir N, Tam J and Dresner-Pollak R: Hepatic adropin is regulated by estrogen and contributes to adverse metabolic phenotypes in ovariectomized mice. Mol Metab. 60:1014822022. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo FY, Cheng KC, Li Y, Cheng JT and Tsai CC: Promotion of adropin expression by hyperglycemia is associated with STAT3 activation in diabetic rats. Diabetes Metab Syndr Obes. 13:2269–2277. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li YX, Cheng KC, Liu IM and Niu HS: Myricetin Increases circulating adropin level after activation of glucagon-like peptide 1 (GLP-1) receptor in type-1 diabetic rats. Pharmaceuticals (Basel). 15:1732022. View Article : Google Scholar : PubMed/NCBI | |
|
Thapa D, Xie B, Manning JR, Zhang M, Stoner MW, Huckestein BR, Edmunds LR, Zhang X, Dedousis NL, O'Doherty RM, et al: Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep. 7:e140432019. View Article : Google Scholar : PubMed/NCBI | |
|
Jasaszwili M, Pruszyńska-Oszmałek E, Wojciechowicz T, Strowski MZ, Nowak KW and Skrzypski M: Adropin slightly modulates lipolysis, lipogenesis and expression of adipokines but not glucose uptake in rodent adipocytes. Genes (Basel). 12:9142021. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HY, Zhao P, Wu MC, Liu J and Yin W: Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 190-191:46–49. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ding F, Liu G, Gao F, Zheng Z, Hong Y, Chen Y and Weng S: Adropin attenuates pancreatitis-associated lung injury through PPARγ phosphorylation-related macrophage polarization. Int J Mol Med. 52:952023. View Article : Google Scholar | |
|
Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, Özgün Çil E, Özcan M, Aydın Yoldemir Ş, Akarsu M, et al: Serum adropin levels are reduced in adult patients with nonalcoholic fatty liver disease. Med Princ Pract. 28:463–469. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Berezina TA, Obradovic Z, Boxhammer E, Berezin AA, Lichtenauer M and Berezin AE: Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure. J Clin Med. 12:22312023. View Article : Google Scholar : PubMed/NCBI | |
|
Kuliczkowska-Płaksej J, Mierzwicka A, Jończyk M, Stachowska B, Urbanovych A and Bolanowski M: Adropin in women with polycystic ovary syndrome. Endokrynol Pol. 70:151–156. 2019. View Article : Google Scholar | |
|
Herrero L, de Dios O, Gavela-Pérez T, Riestra P, Jois A, Soriano-Guillén L and Garcés C: Opposite association of adropin concentrations with obesity in prepubertal children compared with adolescents. Obesity (Silver Spring). 28:1736–1741. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wei W, Liu H, Qiu X, Zhang J, Huang J, Chen H, Qiu S, Lin R, Li S and Tu M: The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: A cross-sectional study. Diabetol Metab Syndr. 14:272022. View Article : Google Scholar | |
|
Zhao LP, You T, Chan SP, Chen JC and Xu WT: Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Exp Ther Med. 11:1065–1070. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liang M, Dickel N, Györfi AH, SafakTümerdem B, Li YN, Rigau AR, Liang C, Hong X, Shen L, Matei AE, et al: Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis. Sci Transl Med. 16:eadd65702024. View Article : Google Scholar : PubMed/NCBI | |
|
Tuna BG, Atalay PB, Altunbek M, Kalkan BM and Dogan S: Effects of chronic and intermittent calorie restriction on adropin levels in breast cancer. Nutr Cancer. 69:1003–1010. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nergiz S, Altinkaya SO, Kurt Ömürlü İ, Yuksel H, Küçük M and Demircan Sezer S: Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol. 31:730–735. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Reed GW, Rossi JE and Cannon CP: Acute myocardial infarction. Lancet. 389:197–210. 2017. View Article : Google Scholar | |
|
Altamimi TR, Gao S, Karwi QG, Fukushima A, Rawat S, Wagg CS, Zhang L and Lopaschuk GD: Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 98:37–48. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Çakmak T and Eren MN: Elevated adropin: A candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. Peptides. 58:91–97. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Wang Z, He Y, Chen T, Zhang Y, Yuan X and Li P: Adropin improves radiation-induced myocardial injury via VEGFR2/PI3K/Akt pathway. Oxid Med Cell Longev. 2022:82302142022.PubMed/NCBI | |
|
Adıyaman M, Canpolat Erkan RE, Kaya İ and Aba Adıyaman Ö: Serum adropin level in the early period of ST-Elevation myocardial infarction and its relationship with cobalamin and folic acid. Cureus. 14:e327482022. | |
|
Chang X, Jin F, Wang L, Jiang Y, Wang P, Liu J and Zhao L: Adropin-A new player in energy regulation predicts long-term prognosis of patients with acute myocardial infarction. Heliyon. 9:e178032023. View Article : Google Scholar | |
|
Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Tervaert JW, Prop J, Camus P, Weening JJ and Kallenberg CG: Antimyeloperoxidase-associated lung disease. An experimental model. Am J Respir Crit Care Med. 160:987–994. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Saeki T, Fujita N, Kourakata H, Yamazaki H and Miyamura S: Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers. Clin Rheumatol. 23:76–80. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gao F, Fang J, Chen F, Wang C, Chen S, Zhang S, Lv X, Zhang J, He Q, Weng S, et al: Enho mutations causing low adropin: A possible pathomechanism of MPO-ANCA Associated lung injury. EBioMedicine. 9:324–335. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rizk FH, El-Saka MH, Ibrahim RR, El-Deeb OS, Ibrahim HA, El Saadany AA, Mashal SS, Ammar L, Abdelsattar AM and Barhoma RA: Possible mitigating effect of adropin on lung injury in diabetic rats: Targeting the role of Rho A/Rho-associated kinase pathway. Biofactors. 49:928–939. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Orun S, Celikkol A, Basol BI and Yeniay E: Diagnostic accuracy of adropin as a preliminary test to exclude acute pulmonary embolism: a prospective study. BMC Pulm Med. 22:3512022. View Article : Google Scholar : PubMed/NCBI | |
|
Byrne CD and Targher G: NAFLD: A multisystem disease. J Hepatol. 62(1 Suppl): S47–S64. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J and Vos MB: Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 69:2672–2682. 2019. View Article : Google Scholar | |
|
Zhang C, Zhang Q, Huang Z and Jiang Q: Adropin inhibited tilapia hepatic glucose output and triglyceride accumulation via AMPK activation. J Endocrinol. 246:109–122. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Sun X, Shen T, Chen Q, Chen S, Pang J, Mi J, Tang Y, You Y, Xu H and Ling W: Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease. Free Radic Biol Med. 160:191–198. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Liu L, Wei Y, Fang C, Liu S, Zhou F, Li Y, Zhao G, Guo Z, Luo Y and Li L: Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: A plausible role of adropin. Lab Invest. 101:369–380. 2021. View Article : Google Scholar | |
|
Li N, Xie G, Zhou B, Qu A, Meng H, Liu J and Wang G: Serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease. Front Physiol. 12:6961632021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Wu X, Li X, Chang X, Ding X, Wang Q, Jiang T, Wang G and Liu J: Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease. Acta Diabetol. 60:971–979. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu T, Du Y, Xuan M, Guo C and Rao X: Clinical characteristics and Chinese Medicine therapy of chronic kidney disease combined with cardiovascular disease. Integr Med Nephrol Androl. 10:e000232023. View Article : Google Scholar | |
|
Song Z and Gong X: research progress on the potential mechanisms of acute kidney injury and chronic kidney disease induced by proton pump inhibitors. Integr Med Nephrol Androl. 10:e000272023. View Article : Google Scholar | |
|
Tao P, Huo J and Chen L: Bibliometric analysis of the relationship between gut microbiota and chronic kidney disease from 2001-2022. Integr Med Nephrol Androl. 11:e000172024. View Article : Google Scholar | |
|
Zhang HQ, Wu S, Chen X, Fang YX, Lan QM, Zhou ZJ, Qiao YH, Li J, Zhao YR, Pei M and Yang B: Potential efficacy and mechanism of medicinal plants on chronic kidney disease-associated vascular calcification: A review. Tradit Med Res. 9:512024. View Article : Google Scholar | |
|
Memi G and Yazgan B: Adropin and spexin hormones regulate the systemic inflammation in adenine-induced chronic kidney failure in rat. Chin J Physiol. 64:194–201. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Grzegorzewska AE, Niepolski L, Mostowska A, Warchoł W and Jagodziński PP: Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients. Life Sci. 160:41–46. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kałużna M, Hoppe K, Schwermer K, Ibrahim AY, Pawlaczyk K and Ziemnicka K: Adropin and irisin levels in relation to nutrition, body composition, and insulin resistance in patients with end-stage renal disease on chronic hemodialysis and peritoneal dialysis. Pol Arch Med Wewn. 126:474–482. 2016. | |
|
Kałużna M, Pawlaczyk K, Schwermer K, Hoppe K, Człapka-Matyasik M, Ibrahim AY, Sawicka-Gutaj N, Minczykowski A, Ziemnicka K, Oko A and Ruchała M: Adropin and irisin: New biomarkers of cardiac status in patients with end-stage renal disease? A preliminary study. Adv Clin Exp Med. 28:347–353. 2019. View Article : Google Scholar | |
|
Cecerska-Heryć E, Adamiak D, Serwin N, Grygorcewicz B and Dołęgowska B: Comparative analysis of adropin concentration changes in response to kidney transplantation. Eur J Intern Med. 84:112–114. 2021. View Article : Google Scholar | |
|
Maciorkowska M, Musiałowska D and Małyszko J: Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Adv Clin Exp Med. 28:1571–1575. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kaur R, Krishan P, Kumari P, Singh T, Singh V, Singh R and Ahmad SF: Clinical significance of adropin and afamin in evaluating renal function and cardiovascular health in the presence of CKD-MBD biomarkers in chronic kidney disease. Diagnostics (Basel). 13:31582023. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Cui B, Zhao X, Wu Y, Qin H, Guo Y, Wang H, Lu M, Zhang S, Shen J, et al: Correlation of serum adropin levels with risk factors of cardiovascular disease in hemodialysis patients. Metab Syndr Relat Disord. 19:401–408. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Boric-Skaro D, Mizdrak M, Luketin M, Martinovic D, Tokic D, Vilovic M, Supe-Domic D, Kurir TT and Bozic J: Serum adropin levels in patients on hemodialysis. Life (Basel). 11:3372021.PubMed/NCBI | |
|
Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, Bicer M and Calan OG: A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest. 39:747–754. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bousmpoula A, Kouskouni E, Benidis E, Demeridou S, Kapeta-Kourkouli R, Chasiakou A and Baka S: Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: Correlation with lipoprotein lipid profiles. Gynecol Endocrinol. 34:153–156. 2018. View Article : Google Scholar | |
|
Inal ZO, Erdem S, Gederet Y, Duran C, Kucukaydin Z, Kurku H and Sakarya DK: The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS. Endokrynol Pol. 69:135–141. 2018.PubMed/NCBI | |
|
Ye Z, Zhang C and Zhao Y: Potential effects of adropin on systemic metabolic and hormonal abnormalities in polycystic ovary syndrome. Reprod Biomed Online. 42:1007–1014. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Varikasuvu SR, Reddy EP, Thangappazham B, Varshney S, Das VL and Munikumar M: Adropin levels and its associations as a fat-burning hormone in patients with polycystic ovary syndrome: A correlational meta-analysis. Gynecol Endocrinol. 37:879–884. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ke Y, Hu J, Zhu Y, Wang Y, Chen S and Liu S: Correlation between circulating adropin levels and patients with PCOS: An updated systematic review and meta-analysis. Reprod Sci. 29:3295–3310. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Engin A: The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 960:1–17. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Ghoshal S, Zhang L, Stevens JR, McCommis KS, Finck BN, Lopaschuk GD and Butler AA: The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 294:13366–13377. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dye L, Boyle NB, Champ C and Lawton C: The relationship between obesity and cognitive health and decline. Proc Nutr Soc. 76:443–454. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Miller AA and Spencer SJ: Obesity and neuroinflammation: A pathway to cognitive impairment. Brain Behav Immun. 42:10–21. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ghoshal S, Banerjee S, Zhang J, Niehoff ML, Farr SA and Butler AA: Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL/6J mice. Peptides. 146:1706782021. View Article : Google Scholar : PubMed/NCBI | |
|
Altincik A and Sayin O: Evaluation of the relationship between serum adropin levels and blood pressure in obese children. J Pediatr Endocrinol Metab. 28:1095–1100. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen RM, Yuan X, Ouyang Q, Lin XQ, Ai ZZ, Zhang Y and Yang XH: Adropin and glucagon-like peptide-2 are associated with glucose metabolism in obese children. World J Pediatr. 15:565–571. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan X, Chen R, Ouyang Q, Lin X, Ai Z, Zhang Y and Yang X: Novel associations of serum adropin and lipopolysaccharide-binding protein versus lipid profiles in childhood obesity. J Pediatr Endocrinol Metab. 33:265–270. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yin C, Zhang H, Zhang M and Xiao Y: Adropin and apelin-12 efficiently predict metabolic syndrome in obese children. Pediatr Diabetes. 21:1132–1139. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Soltani S, Kolahdouz-Mohammadi R, Aydin S, Yosaee S, Clark CCT and Abdollahi S: Circulating levels of adropin and overweight/obesity: A systematic review and meta-analysis of observational studies. Hormones (Athens). 21:15–22. 2022. View Article : Google Scholar | |
|
He L, Zhang FJ, Li HY, Li L, Song LG, Mao Y, Li J, Liu HM, Li FL, Xu LY, et al: Anti-diabetic role of adropin in streptozotocin induced diabetic rats via alteration of PI3K/Akt and insulin signaling pathway. J Oleo Sci. 70:657–664. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hu W and Chen L: Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm. 2016:60382612016. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Li N, Guo S, Zhang M, Li J, Zhai N, Wang H and Zhang Y: The changing features of serum adropin, copeptin, neprilysin and chitotriosidase which are associated with vascular endothelial function in type 2 diabetic retinopathy patients. J Diabetes Complications. 34:1076862020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang S, Young JL, Wang K, Qian Y and Cai L: Diabetic-induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus (Review). Mol Med Rep. 22:603–611. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jones JG: Hepatic glucose and lipid metabolism. Diabetologia. 59:1098–1103. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Thapa D, Xie B, Zhang M, Stoner MW, Manning JR, Huckestein BR, Edmunds LR, Mullett SJ, McTiernan CF, Wendell SG, et al: Adropin treatment restores cardiac glucose oxidation in pre-diabetic obese mice. J Mol Cell Cardiol. 129:174–178. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Skrzypski M, Kołodziejski PA, Pruszyńska-Oszmałek E, Wojciechowicz T, Janicka P, Krążek M, Małek E, Strowski MZ and Nowak KW: Daily treatment of mice with type 2 diabetes with adropin for four weeks improves glucolipid profile, reduces hepatic lipid content and restores elevated hepatic enzymes in serum. Int J Mol Sci. 23:98072022. View Article : Google Scholar : PubMed/NCBI | |
|
Zang H, Jiang F, Cheng X, Xu H and Hu X: Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J. 65:685–691. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Choi HN and Yim JE: Plasma adropin as a potential marker predicting obesity and obesity-associated cancer in korean patients with type 2 diabetes mellitus. J Cancer Prev. 23:191–196. 2018. View Article : Google Scholar | |
|
Soltani S, Beigrezaei S, Malekahmadi M, Clark CCT and Abdollahi S: Circulating levels of adropin and diabetes: A systematic review and meta-analysis of observational studies. BMC Endocr Disord. 23:732023. View Article : Google Scholar : PubMed/NCBI | |
|
Palizban AA, Yazdani AH and Jahanbani-Ardakani H: Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case-control study from Isfahan, Iran. Arch Physiol Biochem. 128:378–381. 2022. View Article : Google Scholar | |
|
Davoodi M, Hesamabadi BK, Ariabood E, Izadi MR, Ghardashi-Afousi A, Bigi MAB, Asvadi-Fard M and Gaeini AA: Improved blood pressure and flow-mediated dilatation via increased plasma adropin and nitrate/nitrite induced by high-intensity interval training in patients with type 2 diabetes. Exp Physiol. 107:813–824. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tičinović Kurir T, Miličević T, Novak A, Vilović M and Božić J: Adropin-potential link in cardiovascular protection for obese male type 2 diabetes mellitus patients treated with liraglutide. Acta Clin Croat. 59:344–350. 2020. | |
|
Wang Q, An Y, Zhang L, Zhang Y, Wang G and Liu J: Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 diabetes. BMC Endocr Disord. 22:3062022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Liu C, Jiang H, Chen BC, Yang X, Xiao M, Xie YQ and Li K: Network pharmacology and verification experiment-based prediction of active components and potential targets of Alpiniae Oxyphyllae Fructus-Saposhnikoviae Radix (Yizhiren-Fangfeng) for treatment of diabetic kidney disease. Tradit Med Res. 8:262023. View Article : Google Scholar | |
|
Liu SM, Yan ZJ, Xiao M and Xie YQ: Mechanistic study of lipid metabolism disorders in diabetic kidney disease treated with GLQMP based on network pharmacology, molecular docking and in vitro experiments. Tradit Med Res. 9:112024. View Article : Google Scholar | |
|
Es-Haghi A, Al-Abyadh T and Mehrad-Majd H: The clinical value of serum adropin level in early detection of diabetic nephropathy. kidney Blood Press Res. 46:734–740. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Ai J, Shuai Z, Tang K, Li Z and Huang Y: Adropin alleviates myocardial fibrosis in diabetic cardiomyopathy rats: A preliminary study. Front Cardiovasc Med. 8:6885862021. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Sun J, Hu W, Liu Y, Lin D, Duan H and Liu F: The association of serum and vitreous adropin concentrations with diabetic retinopathy. Ann Clin Biochem. 56:253–258. 2019. View Article : Google Scholar | |
|
Yang C, DeMars KM and Candelario-Jalil E: Age-Dependent decrease in adropin is associated with reduced levels of endothelial nitric oxide synthase and increased oxidative stress in the rat brain. Aging Dis. 9:322–330. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shahdadian F, Saneei P, Lotfi K, Feizi A, Askari G and Safavi SM: Association of plant-based diets with adropin, atherogenic index of plasma, and metabolic syndrome and its components: A cross-sectional study on adults. Front Nutr. 10:10777092023. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C, DeMars KM, Hawkins KE and Candelario-Jalil E: Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions. Peptides. 81:29–37. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jurrissen TJ, Ramirez-Perez FI, Cabral-Amador FJ, Soares RN, Pettit-Mee RJ, Betancourt-Cortes EE, McMillan NJ, Sharma N, Rocha HNM, Fujie S, et al: Role of adropin in arterial stiffening associated with obesity and type 2 diabetes. Am J Physiol Heart Circ Physiol. 323:H879–H891. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, Mori Y, Hirano T and Watanabe T: Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci. 19:12932018. View Article : Google Scholar : PubMed/NCBI | |
|
Li L and Xie W: LncRNA HDAC11-AS1 suppresses atherosclerosis by inhibiting HDAC11-Mediated adropin histone deacetylation. J Cardiovasc Transl Res. 15:1256–1269. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ying T, Wu L, Lan T, Wei Z, Hu D, Ke Y, Jiang Q and Fang J: Adropin inhibits the progression of atherosclerosis in ApoE(−/−)/Enho(−/−) mice by regulating endothelial-to-mesenchymal transition. Cell Death Discov. 9:4022023. View Article : Google Scholar | |
|
Abbasian S, Ravasi AA, Soori R and Aydin S, Choobineh S and Aydin S: High-intensity interval training ameliorates endothelial dysfunction through adropin, nitric oxide, MR-proADM, and copeptin changes in overweight subjects. Hormones (Athens). 21:707–717. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kamma E, Lasisi W, Libner C, Ng HS and Plemel JR: Central nervous system macrophages in progressive multiple sclerosis: Relationship to neurodegeneration and therapeutics. J Neuroinflammation. 19:452022. View Article : Google Scholar : PubMed/NCBI | |
|
McGinley MP, Goldschmidt CH and Rae-Grant AD: Diagnosis and treatment of multiple sclerosis: A review. JAMA. 325:765–779. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cinkir U, Bir LS, Topsakal S, Avci Cicek E and Tekin S: Investigation of blood leptin and adropin levels in patients with multiple sclerosis: A CONSORT-clinical study. Medicine (Baltimore). 100:e272472021. View Article : Google Scholar : PubMed/NCBI | |
|
Algul S and Ozcelik O: Evaluating the energy regulatory hormones of nesfatin-1, irisin, adropin and preptin in multiple sclerosis. Mult Scler Relat Disord. 68:1042212022. View Article : Google Scholar : PubMed/NCBI | |
|
Demirdöğen F, Akdağ T, Gündüz ZB and Odabaş FO: Investigation of serum adropin levels and its relationship with hypothalamic atrophy in patients with multiple sclerosis. Mult Scler Relat Disord. 67:1039992022. View Article : Google Scholar | |
|
Rao A and Herr DR: G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim Biophys Acta Mol Cell Res. 1864:1318–1327. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stelcer E, Milecka P, Komarowska H, Jopek K, Tyczewska M, Szyszka M, Lesniczak M, Suchorska W, Bekova K, Szczepaniak B, et al: Adropin stimulates proliferation and inhibits adrenocortical steroidogenesis in the human adrenal carcinoma (HAC15) cell line. Front Endocrinol (Lausanne). 11:5613702020. View Article : Google Scholar : PubMed/NCBI | |
|
Jia L, Liao L, Jiang Y, Hu X, Lu G, Xiao W, Gong W and Jia X: Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression. BMC Cancer. 23:10422023. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Wu Q, Ding Q, Wu W, Li Q and Zheng Z: High level of adropin promotes the progression of pancreatic ductal adenocarcinoma. Curr Cancer Drug Targets. 24:629–641. 2024. View Article : Google Scholar | |
|
Butler AA and Havel PJ: Adropin and insulin resistance: Integration of endocrine, circadian, and stress signals regulating glucose metabolism. Obesity (Silver Spring). 29:1799–1801. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Smati S, Régnier M, Fougeray T, Polizzi A, Fougerat A, Lasserre F, Lukowicz C, Tramunt B, Guillaume M, Burnol AF, et al: Regulation of hepatokine gene expression in response to fasting and feeding: Influence of PPAR-α and insulin-dependent signalling in hepatocytes. Diabetes Metab. 46:129–136. 2020. View Article : Google Scholar | |
|
Ozkan A, Aslan MA, Sinen O, Munzuroglu M, Derin N, Parlak H, Bulbul M and Agar A: Effects of adropin on learning and memory in rats tested in the Morris water maze. Hippocampus. 32:253–263. 2022. View Article : Google Scholar : PubMed/NCBI |
